Sonnet BioTherapeutics Completes Enrollment in Phase 1 Study of SON-1010 (IL12-FHAB) as a Monotherapy (SB101) for the Treatment of Solid Tumors
Provided By GlobeNewswire
Last update: Sep 18, 2024
SON-1010 is a targeted immune activation cancer therapy designed to turn ‘cold’ tumors ‘hot’
Topline safety data of SB101 Phase 1 study expected by Q4 2024
Read more at globenewswire.comNASDAQ:SONN (2/21/2025, 8:00:02 PM)
1.44
+0.01 (+0.7%)
Find more stocks in the Stock Screener
